Metagenomi (NASDAQ:MGX) Cut to “Sell” at Wall Street Zen

Wall Street Zen lowered shares of Metagenomi (NASDAQ:MGX) from a hold rating to a sell rating in a research report report published on Saturday morning.

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of Metagenomi in a report on Monday, December 22nd. One investment analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $10.00.

Metagenomi Stock Up 0.7%

Shares of MGX stock opened at $1.43 on Friday. Metagenomi has a 12 month low of $1.23 and a 12 month high of $3.95. The business’s 50 day moving average is $1.55 and its two-hundred day moving average is $1.90. The company has a market cap of $53.80 million, a PE ratio of -0.60 and a beta of 0.45.

Metagenomi (NASDAQ:MGX) last issued its quarterly earnings data on Thursday, March 5th. The company reported ($0.60) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.58) by ($0.02). The firm had revenue of $3.91 million during the quarter, compared to analyst estimates of $7.33 million. Metagenomi had a negative return on equity of 47.14% and a negative net margin of 348.54%. As a group, equities analysts expect that Metagenomi will post -2.46 EPS for the current fiscal year.

Institutional Investors Weigh In On Metagenomi

Several hedge funds have recently modified their holdings of MGX. XTX Topco Ltd grew its stake in shares of Metagenomi by 353.4% in the fourth quarter. XTX Topco Ltd now owns 68,994 shares of the company’s stock worth $112,000 after acquiring an additional 53,778 shares during the last quarter. Quadrature Capital Ltd acquired a new position in Metagenomi during the 4th quarter valued at $55,000. Bridgeway Capital Management LLC boosted its holdings in Metagenomi by 102.1% in the 4th quarter. Bridgeway Capital Management LLC now owns 395,800 shares of the company’s stock valued at $641,000 after purchasing an additional 200,000 shares during the period. Panagora Asset Management Inc. bought a new stake in Metagenomi in the 4th quarter valued at $53,000. Finally, Wells Fargo & Company MN grew its position in Metagenomi by 16.1% in the 4th quarter. Wells Fargo & Company MN now owns 118,410 shares of the company’s stock worth $192,000 after purchasing an additional 16,402 shares during the last quarter.

About Metagenomi

Metagenomi, Inc (NASDAQ: MGX) is a biotechnology company that specializes in the discovery and engineering of novel proteins and enzymes using metagenomics and CRISPR-based genome editing. The company’s proprietary platform integrates vast environmental DNA libraries with advanced machine learning and high-throughput screening to identify, optimize and commercialize enzymes for industrial, agricultural and pharmaceutical applications. By tapping into genetic diversity found in nature, Metagenomi aims to accelerate the development of tailored biocatalysts that improve process efficiency, reduce costs and support sustainability initiatives.

Metagenomi’s technology offerings include custom enzyme discovery services, protein engineering tools and licensing of optimized biocatalysts to partners across multiple sectors.